文献速递肺结节与肺癌

非小细胞肺癌治疗时机与结局关联的系统综述

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.
PubMed 文献 · Thorax · 2021-08-17

结果显示,及时治疗在晚期患者中多与更差预后相关(6/8项研究),但在早期手术患者中与更好结局相关(9/12项研究),一项随机对照试验支持在I-IIIA期患者中及时治疗有利。

要点

  • 早期可手术的非小细胞肺癌患者可能从及时治疗中获益更多。
  • 晚期患者中及时治疗与更差预后的关联可能受症状负荷和体能状态影响。
  • 现有证据以观察性研究为主,解读治疗时机对预后影响需谨慎。

核心结论

  • 观察趋势提示治疗及时性对手术候选者尤为重要,晚期患者生存趋势可能被症状负担、体能状态或临床紧急程度所掩盖。

主要发现

  • 晚期疾病患者中,及时治疗普遍与更差预后相关(6/8项研究)。
  • 早期疾病接受手术治疗的患者中,及时治疗与更好结局相关(9/12项研究)。
  • 一项研究中,鳞状细胞癌患者转诊接受立体定向消融放疗时,相比腺癌患者从及时治疗中获益更多。
  • 一项随机对照试验支持在I-IIIA期疾病患者中及时治疗具有优势。

临床怎么用

  • 对早期可手术的非小细胞肺癌患者,应重视及时转诊和治疗以减少可避免延迟。
  • 对晚期患者,治疗决策需综合评估症状负担、体能状态和临床紧急程度,而非单纯追求时间指标。

局限性

  • 现有证据存在局限性,绝大多数为观察性研究,仅一项随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National targets for timely diagnosis and management of a potential cancer are driven in part by the perceived risk of disease progression during avoidable delays. However, it is unclear to what extent time-to-treatment impacts prognosis for patients with non-small cell lung cancer, with previous reviews reporting mixed or apparently paradoxical associations. This systematic review focuses on potential confounders in order to identify particular patient groups which may benefit most from timely delivery of care. METHODS: Medline, EMBASE and Cochrane databases were searched for publications between January 2012 and October 2020, correlating timeliness in secondary care pathways to patient outcomes. The protocol is registered with PROSPERO (the International Prospective Register of Systematic Reviews; ID 99239). Prespecified factors (demographics, performance status, histology, stage and treatment) are examined through narrative synthesis. RESULTS: Thirty-seven articles were included. All but two were observational. Timely care was generally associated with a worse prognosis in those with advanced stage disease (6/8 studies) but with better outcomes for patients with early-stage disease treated surgically (9/12 studies). In one study, patients with squamous cell carcinoma referred for stereotactic ablative radiotherapy benefited more from timely care, compared with patients with adenocarcinoma. One randomised controlled trial supported timeliness as being advantageous in those with stage I-IIIA disease. CONCLUSION: There are limitations to the available evidence, but observed trends suggest timeliness to be of particular importance in surgical candidates. In more advanced disease, survival trends are likely outweighed by symptom burden, performance status or clinical urgency dictating timeliness of treatment.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Hall H, Tocock A, Burdett S, et al. Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review. Thorax. 2021. PMID: 34404753. doi:10.1136/thoraxjnl-2021-216865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。